CoChat

Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1

Open access
Zhu, Yinghua, Liu, Yujie, Zhang, Chao, Chu, Junjun, Wu, Yanqing, Li, Yudong, Liu, Jieqiong, Li, Qian, Li, Shunying, Shi, Qianfeng, Jin, Liang, Zhao, Jianli, Yin, Dong, Efroni, Sol, Su, Fengxi, Yao, Herui, Song, Erwei, Liu, Qiang · 2018 · Nature Communications
Cited by 172

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Tamoxifen resistance is accountable for relapse in many ER-positive breast cancer patients. Most of these recurrent patients receive chemotherapy, but their chemosensitivity is unknown. Here, we report that tamoxifen-resistant breast cancer cells express significantly more BARD1 and BRCA1, leading to resistance to DNA-damaging chemotherapy including cisplatin and adriamycin, but not to paclitaxel. Silencing BARD1 or BRCA1 expression or inhibition of BRCA1 phosphorylation by Dinaciclib restores the sensitivity to cisplatin in tamoxifen-resistant cells. Furthermore, we show that activated PI3K/AKT pathway is responsible for the upregulation of BARD1 and BRCA1. PI3K inhibitors decrease the expression of BARD1 and BRCA1 in tamoxifen-resistant cells and re-sensitize them to cisplatin both in vitro and in vivo. Higher BARD1 and BRCA1 expression is associated with worse prognosis of early breast cancer patients, especially the ones that received radiotherapy, indicating the potential use of PI3K inhibitors to reverse chemoresistance and radioresistance in ER-positive breast cancer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-018-03951-0

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 172

Metadata

Authors
Zhu, Y., Liu, Y., Zhang, C., Chu, J., Wu, Y., Li, Y., Liu, J., Li, Q., Li, S., Shi, Q., Jin, L., Zhao, J., Yin, D., Efroni, S., Su, F., Yao, H., Song, E., & Liu, Q.
Venue
Nature Communications
Published
2018-04-23
Volume
9
Issue
1
Pages
1595-1595
ISSN
2041-1723 (ISSN-L)
OpenAlex
W2801387246
Cited by
172
References
4
FWCI
3.93
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1. https://app.cochat.ai/papers/10.1038/s41467-018-03951-0
The paper
Zhu, Y., Liu, Y., Zhang, C., Chu, J., Wu, Y., Li, Y., Liu, J., Li, Q., Li, S., Shi, Q., Jin, L., Zhao, J., Yin, D., Efroni, S., Su, F., Yao, H., Song, E., & Liu, Q. (2018). Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1. Nature Communications. https://doi.org/10.1038/s41467-018-03951-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.